Stock

Silexion Therapeutics

SLXN

Biotechnology · Healthcare

Price

$0.34

-0.00 (-0.38%)

Market Cap

$143,967

Exchange

NASDAQ Global Market

Winston Score

–

No score yet — nothing to grade.

This is a pre-revenue company — it has no sales yet, just exploration or development costs. There’s no operating business to grade on profitability, margins or cash flow, so the Winston Score stays blank until it starts booking revenue.

Track this stock — start free trial

Share count rising — dilution

+1108.3% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 11K (2021) → 133K (2025)

§Winston Score History

The full picture

Silexion Therapeutics is a clinical-stage biotechnology company developing treatments for pancreatic cancer. Its lead drug candidate, called SIL-204 (formerly known as siG12D-LODER), uses RNA interference technology to silence a specific gene mutation that drives tumor growth. The company is focused on one of the hardest-to-treat cancers, where survival rates remain very low.

Because Silexion is still in clinical trials, it does not yet generate product revenue. The company is headquartered in Israel and went public through a merger with a special purpose acquisition company. Its small size means it relies on capital raises to fund operations. The key potential growth driver is positive data from its ongoing clinical trials in pancreatic cancer, but the main risk is significant — most experimental cancer drugs fail in development, and the company faces a long path to potential commercialization with no guarantee of success.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

Revenue data limited

EPS Growth

+88.0% YoY

YoY Growth Rate

EPS growth accelerating

R&D Spend

$7M/ year

↑ Rising (+23% vs prior year)

R&D investment increasing — building for the future

Insider Activity

1.0%ownership

Relatively low insider ownership

Cash Runway

~2 months

$2M cash & investments

Quarterly Free Cash Flow

→ Burn rate stable

Short runway — potential dilution ahead through share issuance

Cash watch

Silexion Therapeutics has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

N/A

—

Data not available

Profit after running costs

Operating Margin

N/A

—

Data not available

Return on the money invested

ROCE

887.9%

Exceptional — 887.9% return on capital

ROIC above 25%. Every dollar invested in the business earns more than 25 cents back per year.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

N/A

—

Data not available

Profit growth

EPS YoY

N/A

Data not available

How steady the profit is

EPS Consistency

7/8 quarters

Every recent quarter grew earnings vs last year

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

—

Data not available

Spare cash per sale

FCF Margin

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

22.39

Heavy debt load (22.39)

Covers its interest

Interest Cover

1522.83x

Comfortably covers interest (1522.8x)

Interest coverage above 8. Profits cover interest many times over.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

—

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial